Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Anti-IL13RA2 CAR-T cells |
Synonyms | |
Therapy Description |
Anti-IL13RA2 CAR T cells are T-cells that express a chimeric antigen receptor that targets the IL13RA2, which potentially results in anti-tumor activity (PMID: 29103912). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Anti-IL13RA2 CAR-T cells | Anti-IL13RA2 CAR T cells | Anti-IL13RA2 CAR-T cells are T-cells engineered to express a chimeric antigen receptor (CAR) targeting IL13RA2, which may induce antitumor activity (PMID: 29103912). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04003649 | Phase I | Anti-IL13RA2 CAR-T cells Anti-IL13RA2 CAR-T cells + Ipilimumab + Nivolumab Anti-IL13RA2 CAR-T cells + Nivolumab | IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM | Recruiting | USA | 0 |